Figure 3From: High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility studyPathological features of a subcutaneous lesion biopsied after 3 cycles of therapy showing a diffuse regression of the neoplastic cells with abundant melanocitic pigment.Back to article page